| Name | furegrelate sodium |
|---|---|
| Synonyms |
Sodium 5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate
Fureelate Sodium (U-63557A) Sodium 5-(3-pyridinylmethyl)-2-benzofurancboxylate sodium styrene sulphonate p-styrenesulfonic acid sodium salt sodium styrene-4-sulphonate Sodium 5-(3-pyridinylmethyl)-1-benzofuran-2-carboxylate furealate sodium 5-(3-Pyridinylmethyl)benzofurancboxylic acid sodium-potassium salt sodium 4-styrenesulfonate FUREELATE SODIUM SODIUM FUREELATE Sodium p-Styrenesulfonate 4-Vinylbenzenesulfonic acid sodium salt FUREELATE SODIUM SALT sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-cboxylate 5-(3-PYRIDINYLMETHYL)-2-BENZOFURANCBOXYLIC ACID, SODIUM SALT sodium styrene sulfonate Styrene-4-sulfonic acid sodium salt 5-(3'-Pyridinylmethyl)benzofuran-2-cboxylate sodium 5-(3-Pyridinylmethyl)-2-benzofurancarboxylic Acid Sodium Salt 2-Benzofurancboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt U-63557A Fureelate sodium, 10 mM in DMSO teries,hypertension,available,Fureelate,inhibit,orally,antiplatelet,platelet,terial,human,stenosed,Inhibitor,pulmony,Fureelate sodium,corony 2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt (1:1) 5-[3,PYRIDINYLMETHYL]BENZO-FURAN-CBOXYLIC ACID SODIUM SALT 5-(3-Pyridylmethyl)benzofuran-2-cboxylic acid sodium salt C15H11NO3.Na Sodium 4-vinylbenzenesulfonate |
| Description | Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery[1]. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1]. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2]. Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme[2]. Animal Model: Mongrel dogs (19-30 kg)[1] Dosage: 1-5 mg/kg Administration: Oral (via a gastric tube) Result: Prevented blockage of the coronary artery. |
| References |
| Boiling Point | 458.7ºC at 760 mmHg |
|---|---|
| Molecular Formula | C15H10NNaO3 |
| Molecular Weight | 275.235 |
| Flash Point | 231.2ºC |
| Exact Mass | 275.055847 |
| PSA | 66.16000 |
| LogP | 1.78210 |
|
~96%
85666-17-7 |
| Literature: Johnson; Nidy; Aiken; Crittenden; Gorman Journal of medicinal chemistry, 1986 , vol. 29, # 8 p. 1461 - 1468 |
|
~%
85666-17-7 |
| Literature: Johnson; Nidy; Aiken; Crittenden; Gorman Journal of medicinal chemistry, 1986 , vol. 29, # 8 p. 1461 - 1468 |
|
~%
85666-17-7 |
| Literature: Johnson; Nidy; Aiken; Crittenden; Gorman Journal of medicinal chemistry, 1986 , vol. 29, # 8 p. 1461 - 1468 |
|
~%
85666-17-7 |
| Literature: Johnson; Nidy; Aiken; Crittenden; Gorman Journal of medicinal chemistry, 1986 , vol. 29, # 8 p. 1461 - 1468 |
|
~%
85666-17-7 |
| Literature: Johnson; Nidy; Aiken; Crittenden; Gorman Journal of medicinal chemistry, 1986 , vol. 29, # 8 p. 1461 - 1468 |
| Precursor 5 | |
|---|---|
| DownStream 0 | |